The 4th Systemic Sclerosis World Congress will take place in Lisbon, Portugal, from 18th to 20th February and Scleroderma News will be covering the whole event. Even though this is a systemic sclerosis (SSc) congress, a lot will be discussed about pulmonary arterial hypertension (PAH), which is considered a leading cause of mortality among systemic scleroderma patients.
Therefore, we decided to chose one article per satellite symposium that Scleroderma News team is planning to cover. Here are the articles:
Findings collected during more than two years confirming the safety and efficacy of Bayer’s Adempas® (riociguat) in treating either inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), and patients with pulmonary arterial hypertension (PAH) were recently presented at the European Respiratory Society (ERS) Congress.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?